HA
AVBP icon

HHLR Advisors’s ArriVent BioPharma AVBP Stock Holding History

HHLR Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90.6M Hold
3,929,117
– – 5.42% 6
2025
Q4 		$79.1M Sell
3,929,117
-555,555
-12% -$11.6M 2.55% 6
2025
Q3 		$82.7M Hold
4,484,672
– – 2.02% 9
2025
Q2 		$97.6M Hold
4,484,672
– – 3.14% 9
2025
Q1 		$82.9M Hold
4,484,672
– – 2.34% 11
2024
Q4 		$119M Hold
4,484,672
– – 4.14% 8
2024
Q3 		$105M Hold
4,484,672
– – 2.31% 9
2024
Q2 		$83.2M Buy
4,484,672
+555,555
+14% +$9.91M 2.05% 8
2024
Q1 		$70.2M Buy
+3,929,117
New +$79.3M 1.52% 12

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

HHLR Advisors's AVBP Position: Q1 2026 in Review

HHLR Advisors held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 3,929,117 shares worth $90.6M. The position accounts for 5.42% of the portfolio, ranked #6.

HHLR Advisors first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $119M in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • HHLR Advisors held 3,929,117 shares of ArriVent BioPharma worth $90.6M as of Q1 2026.
  • HHLR Advisors left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up 5.42% of HHLR Advisors's portfolio in Q1 2026, its #6 holding.
  • HHLR Advisors first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • HHLR Advisors's ArriVent BioPharma position peaked at $119M in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on HHLR Advisors's 13F filing for Q1 2026, filed 15 May 2026.